Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Rudzinski ER, Anderson JR, Chi YY, Gastier-Foster JM, Astbury C, Barr FG, Skapek SX, Hawkins DS, Weigel BJ, Pappo A, Meyer WH, Arnold MA, Teot LA, Parham DM.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26645. Epub 2017 May 18.

PMID:
28521080
2.

Targeted therapy for soft tissue sarcomas in adolescents and young adults.

Steppan DA, Pratilas CA, Loeb DM.

Adolesc Health Med Ther. 2017 Mar 30;8:41-55. doi: 10.2147/AHMT.S70377. eCollection 2017. Review.

3.

Molecular diagnostics in the management of rhabdomyosarcoma.

Arnold MA, Barr FG.

Expert Rev Mol Diagn. 2017 Feb;17(2):189-194. doi: 10.1080/14737159.2017.1275965. Epub 2017 Jan 6. Review.

PMID:
28058850
4.

Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.

Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, Zylber RJ, Pang J, Diolaiti D, Koval C, Andrews SJ, Garvin JH, Yamashiro DJ, Chung WK, Emerson SG, Nagy PL, Mansukhani MM, Kung AL.

Genome Med. 2016 Dec 23;8(1):133. doi: 10.1186/s13073-016-0389-6.

5.

MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas.

Missiaglia E, Shepherd CJ, Aladowicz E, Olmos D, Selfe J, Pierron G, Delattre O, Walters Z, Shipley J.

Cancer Lett. 2017 Jan 28;385:251-260. doi: 10.1016/j.canlet.2016.10.011. Epub 2016 Oct 29.

6.

LEF1 reduces tumor progression and induces myodifferentiation in a subset of rhabdomyosarcoma.

Dräger J, Simon-Keller K, Pukrop T, Klemm F, Wilting J, Sticht C, Dittmann K, Schulz M, Leuschner I, Marx A, Hahn H.

Oncotarget. 2017 Jan 10;8(2):3259-3273. doi: 10.18632/oncotarget.13887.

7.

Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.

Böhm M, Wachtel M, Marques JG, Streiff N, Laubscher D, Nanni P, Mamchaoui K, Santoro R, Schäfer BW.

J Clin Invest. 2016 Nov 1;126(11):4237-4249. doi: 10.1172/JCI85057. Epub 2016 Oct 17.

8.

Advances in sarcoma diagnostics and treatment.

Dancsok AR, Asleh-Aburaya K, Nielsen TO.

Oncotarget. 2017 Jan 24;8(4):7068-7093. doi: 10.18632/oncotarget.12548. Review.

9.

Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma.

Bersani F, Lingua MF, Morena D, Foglizzo V, Miretti S, Lanzetti L, Carrà G, Morotti A, Ala U, Provero P, Chiarle R, Singer S, Ladanyi M, Tuschl T, Ponzetto C, Taulli R.

Cancer Res. 2016 Oct 15;76(20):6095-6106. Epub 2016 Aug 28.

10.

p38α MAPK disables KMT1A-mediated repression of myogenic differentiation program.

Chatterjee B, Wolff DW, Jothi M, Mal M, Mal AK.

Skelet Muscle. 2016 Aug 22;6:28. doi: 10.1186/s13395-016-0100-z. eCollection 2016.

11.

The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion.

Jaaks P, D'Alessandro V, Grob N, Büel S, Hajdin K, Schäfer BW, Bernasconi M.

PLoS One. 2016 Aug 22;11(8):e0161396. doi: 10.1371/journal.pone.0161396. eCollection 2016.

12.

Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma.

Sabnis AJ, Guerriero CJ, Olivas V, Sayana A, Shue J, Flanagan J, Asthana S, Paton AW, Paton JC, Gestwicki JE, Walter P, Weissman JS, Wipf P, Brodsky JL, Bivona TG.

Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9015-20. doi: 10.1073/pnas.1603883113. Epub 2016 Jul 22.

13.

The RhoE/ROCK/ARHGAP25 signaling pathway controls cell invasion by inhibition of Rac activity.

Thuault S, Comunale F, Hasna J, Fortier M, Planchon D, Elarouci N, De Reynies A, Bodin S, Blangy A, Gauthier-Rouvière C.

Mol Biol Cell. 2016 Sep 1;27(17):2653-61. doi: 10.1091/mbc.E16-01-0041. Epub 2016 Jul 13.

14.

PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.

Hanna JA, Garcia MR, Go JC, Finkelstein D, Kodali K, Pagala V, Wang X, Peng J, Hatley ME.

Cell Death Dis. 2016 Jun 9;7(6):e2256. doi: 10.1038/cddis.2016.159.

15.

The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.

Mohamed A, Sun C, De Mello V, Selfe J, Missiaglia E, Shipley J, Murray GI, Zammit PS, Wackerhage H.

J Pathol. 2016 Sep;240(1):3-14. doi: 10.1002/path.4745.

17.

MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.

Chang W, Brohl AS, Patidar R, Sindiri S, Shern JF, Wei JS, Song YK, Yohe ME, Gryder B, Zhang S, Calzone KA, Shivaprasad N, Wen X, Badgett TC, Miettinen M, Hartman KR, League-Pascual JC, Trahair TN, Widemann BC, Merchant MS, Kaplan RN, Lin JC, Khan J.

Clin Cancer Res. 2016 Aug 1;22(15):3810-20. doi: 10.1158/1078-0432.CCR-15-2717. Epub 2016 Mar 18.

18.

Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes.

Morena D, Maestro N, Bersani F, Forni PE, Lingua MF, Foglizzo V, Šćepanović P, Miretti S, Morotti A, Shern JF, Khan J, Ala U, Provero P, Sala V, Crepaldi T, Gasparini P, Casanova M, Ferrari A, Sozzi G, Chiarle R, Ponzetto C, Taulli R.

Elife. 2016 Mar 17;5. pii: e12116. doi: 10.7554/eLife.12116.

19.

Alveolar rhabdomyosarcoma of nasopharynx and paranasal sinuses with metastasis to breast in a middle-aged woman: a case report and literature review.

Liu H, Zhao W, Huang M, Zhou X, Gong Y, Lu Y.

Int J Clin Exp Pathol. 2015 Nov 1;8(11):15316-21. eCollection 2015. Review.

20.

Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma.

Vleeshouwer-Neumann T, Phelps M, Bammler TK, MacDonald JW, Jenkins I, Chen EY.

PLoS One. 2015 Dec 4;10(12):e0144320. doi: 10.1371/journal.pone.0144320. eCollection 2015.

Supplemental Content

Support Center